By pairing medication with patient-first care, employers can improve long-term outcomes, adherence, and potentially reduce reliance on expensive drugs over time
Discussion This study adds to the limited available data on the use of semaglutide in patients with advanced CKD and provides insight over a prolonged follow-up period exceeding three years (median 1,187 days [IQR 6021,442]), with the majority of patients receiving maintenance hemodialysis (58.8%)
This combination enhances its ability to regulate metabolism by activating two hormone receptors instead of one, potentially leading to more effective treatment outcomes
Of note, a small number of cases of acute pancreatitis associated with GLP-1RA use have been reported in clinical trials: 38 cases in 17,775 patient-years of exposure compared with 9 events in 5863 patient-years of exposure with the comparator treatment
A 1.5 percentage point absolute reduction and a 20 percent relative reduction